Figure 8: Proposed model of dovitinib-mediated autophagy and apoptosis with regard to the SHP-1/p-STAT3 pathway in breast cells. In breast cancer cells, dovitinib inhibit STAT3 phosphorylation and induced autophagy, in part, via releasing of beclin 1 from Mcl-1. Dovitinib also involved in SHP-1 activation and induced apoptotic cell death by downregulating of p-STAT3/cyclin D1 axis and increasing cleaved PARP expression. Accordingly, the present study may provide information regarding the association of autophagy and apoptosis with dovitinib chemotherapy in breast cancer cells, and the regulation of SHP-1/p-STAT3 pathway may be a promising strategy for treating breast cancer cells in response to RTKs inhibitors-based drugs, such as dovitinib.